Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels
Editorial

Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels

Giulia Malaguarnera1, Saverio Latteri2, Vito Emanuele Catania2, Michele Malaguarnera1

1Research Center "The Great Senescence", University of Catania, Catania, Italy; 2Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, Catania, Italy

Correspondence to: Michele Malaguarnera. Research Center "The Great Senescence", University of Catania, Via Messina No. 829, 95126 Catania, Italy. Email: m.malaguarnera@email.it.

Provenance: This is an invited Editorial commissioned by the Section Editor Yongming He (Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou, China).

Comment on: Perrot N, Verbeek R, Sandhu M, et al. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis 2017;256:47-52.


Submitted Mar 27, 2017. Accepted for publication Aug 04, 2017.

doi: 10.21037/jtd.2017.08.67


Lipoprotein (a) [Lp (a)] is a plasma lipoprotein consisting of a cholesterol rich LDL particle with one molecule of apolipoprotein B100 and one protein apolipoprotein (a) [apo(a)].

The two molecules are most likely assembled in the hepatocyte cellular membrane and are connected biochemically by a disulfide bridge through cysteine residues within apo(a) (Cys 4057) and apoB100 (Cys 4326).

Lp(a) closely resembles a low-density lipoprotein (LDL) particle but is found across the continuum of lipoprotein particles including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) (1-3).

The lipoprotein (a) is directly synthesized by the liver, which releases different isoforms in blood circulation. The heterogeneity of the lipoprotein is genetically determined by the size of apo B100, which in turn is controlled by several alleles of the apo (a) gene (4).

Apo(a) synthesis is dependent on ApoB synthesis (explaining elevated levels of Lp(a) in individuals with familiar hypercholesterolemia), but possibly form a different pool of ApoB 100 than that associated with LDL particle assembly (5).

Within apo (a) is a unique region highly structurally homologous to plasminogen but devoid of protease activity.

By antagonizing plasminogen binding, Lp(a) may play a role in hemostasis and wound healing at sites of arterial injury, attenuating fibrinolysis, promoting thrombosis, coagulation and delivering cholesterol.

Apoprotein(a) is genetically very heterogeneous due to variation in molecular weight secondary to differences in the number of Kringle repeats (6,7).

Apo (a) contains multiple copies of plasminogen-like Kringle IV (KIV) sequences, followed by sequences closely resembling plasminogen Kringle V and an inactive protease domain (8,9).

Lp(a) concentration have a more than 1000-fold inter-individual range that is to a large extent genetically determined up to 70% of the concentrations are explained by a highly polymorphic copy number variation within the LPA gene region that was already described than 25 years ago (10,11).

Recently a genome-wide association study has identified a genetic variant in the LPA gene locus which encodes apolipoprotein (a), determining plasma levels of lipoprotein (a). Although LPA variants have been associated with CHD and aortic valve stenosis (12), four single nucleotide polymorphism (SNPs) in the LPA gene had been associated with plasma Lp(a) levels: rs 10455872, rs 3798220, rs 41272114 and rs 143431368.

The rs 3798220 and rs 10455872 single nucleotide polymorphisms (SNPs), which were most strongly associated with Lp(a) levels, were most strongly associated with coronary disease risk (13).

Epidemiological evidence associate elevated Lp(a) concentration with increased cardiovascular risk and predict adverse outcome in atherosclerotic disease. Lp(a) is also associated with peripheral arterial disease, venous thromboembolism, cerebral vascular disease, abdominal aorta aneurism, aortic valve stenosis and calcification (14,15). The mechanism by which an increased level of Lp(a) increases the risk of coronary disease is less well understood; it may involve LDL lipoprotein cholesterol, the inhibition of conversion of plasminogen to plasmin, the inhibition of the expression of tissue factor or the carriage of pro-inflammatory oxidized phospholipids.

The consistent observation of a strong correlation between the circulating levels of Lp(a) and oxidized/phospholipid/apolipoprotein B complex which were together directly associated with CVD outcomes suggested to them that Lp(a) transported the pro-inflammatory burden of oxidized phospholipids. In prospective cohort studies, these findings were attributed to the possible increased efflux from plaques of oxidized lipoprotein complex. Moreover it has been demonstrated that lipoprotein complex were associated with angiographic coronary artery disease (16).

In fact elevated Lp(a) level is believed to promote atherosclerosis via Lp(a)-derived cholesterol entrapment in the intima, inflammatory cell recruitment and/or via the binding of pro-inflammatory-oxidised LDL (17-22).

Elevated Lp(a) level promote also thrombosis via the inhibition of fibrinolysis with enhancement of clot stabilization as well as via enhancement coagulation via the inhibition of tissue factor pathway inhibitor.

The relationship between Lp(a) and endothelial dysfunction and pro-inflammatory properties of Lp (a) may be considered as additional explanations.

Experimental studies have shown that Lp(a) may contribute to foam cell formation (23).

The possibility that Lp(a) may become functionally altered in patients with coronary artery disease has been put forward by Tsironis on the basis of mass and specific activity of Lp(a) as mediator of platelet activating factor acetyl-hydrolase activity, an enzyme that hydrolyses oxidized phospholipids (24,25).

The current pharmaceutical armamentarium to lower Lp(a) levels is limited to niacin, L-Carnitine, PCSSK inhibitors and oestrogen.

Nicotinic acid (NA) based treatment (e.g., Tredaptive) was previously felt to be modest effective at lowering LP(a) (26).

The major effect of NA is the partial inhibition of lipolysis from the adipose tissue, resulting in a decreased flux of free fatty acid to the liver, reducing the VLDL production rate.

NA reduces Lp(A) by up to 40% and has been identified as the drug that lowering Lp(a). However several studies have demonstrated that NA treatment is associated with hyperglycaemia and insulin resistance (27).

L-Carnitine plays an important role in fatty acid metabolism and Acetyl-L-carnitine in hepatic their subsequent transport into mitochondrial matrix, where they undergo beta-oxidation for cellular energy production (28-31). L-carnitine treatment decrease Lp(a) levels by about 20%.

Data assessing the impact of statins on LP (a) are limited and highly variable and overall, statins are ineffective at significantly LP (a) (32-34).

In a study by Yeang and colleagues, Lp(a) and Ox Pl-apoB were measured pre- and post-statin therapy the mean patient-level Lp(a) increased by 11% and Ox Pl-apoB increased by 24% (35).

Protein apheresis is a selective lipid lowering extra-corporal treatment by which excess atherogenic apo B-100 containing lipoproteins, including Lp(a) and LDL are removed from blood or plasma (36). Currently, it remains the most effective means of lowering Lp (a) levels (37).

Lipoprotein apheresis is able to produce rapid, prolonged and significant dose-dependent reduction in LDL-cholesterol, apoB100 and other atherogenic apoB (38).

Other Lp(a) treatment are sex hormones therapy, thyroid hormone and inhibitors of interleukine-6 receptor. Sex hormones have an influence on Lp(a) levels. While systemic estrogen alone or in combination with progestin decreases Lp(a), transdermal hormone replacement therapy and the raloxifene selective oestrogen receptor modulator do not effect Lp(a) levels. Tibolone, a synthetic steroid with weak oestrogenic, progestagenic and androgenic properties, has been shown to decrease Lp(a) levels in post-menopausal women.

Tibolone treatment can reduce Lp(a) concentration by 25% (39,40). The mechanism through which sex hormones influence Lp(a) levels is is most likely the down regulation of apo(a) gene expression.

Other novel mechanisms to influence Lp(a) concentrations may involve the inhibitors of interleukin-6 receptor signalling with the Il-6 receptor antibody tocilizumab (41).

The thyroid hormone analogue eprotirome was found to decrease Lp(a) by about 40% (42).

Recent evidence showing that monoclonal antibodies that block proprotein convertase subtilisin/Kexin type 9 (PCSK-9) Evolocumab and Arirocumab, both administered though subcutaneous injections twice per month reduce not only LDL-C, apoB-100, but also Lp(a) concentrations in patient with familiarly hypercholesterolemia (43,44). Inhibitors of the cholesteryl ester transfer protein (CETP) are a new class of lipid-modifying drugs. Anacetrapib has been shown to decrease Lp(a) concentration by about 40% (45). CEPT plays a relevant role in reverse cholesterol transport in humans and its deficiency has been associated with decreased coronary artery diseases (44). Among the promising therapeutic approach the antisense oligonucleotide (ASO) represent a promise in specific targeting of disease-associated genes in dyslipidemia. The most advanced antisense lipid-lowering agent in development is Mipomersen, an apoB-100 synthetises inhibitor. Mipomersen has been shown to significantly decrease Lp(a) concentrations by about 30% (46).

Others ASOs drug reduce Lp(a) up to 80% but are still in phase 1–2 studies (47).

Many studies have shown high levels of Lp(a) (>50 mg/dL) or genotype rs10455872 variant are associated with potential mechanisms that raises cardiovascular risk and grows the atherosclerotic plaque. Perrot et al., in the Epic Norfolk prospective population study evaluated the Cardiovascular Health Score (CHS) in Lp(a) levels or genotype (48).

The Cardiovascular Health Score was calculated on these seven-health metrics with an ideal, intermediate or poor status. The seven components of CHS are body mass index, healthy diet score, physical activity, smoking behaviour, blood pressure, diabetes mellitus and total cholesterol.

This study shows that to reduce cardiovascular disease risk associated with high lipoprotein (a) levels or genotype should be added on top of lifestyle management and on top of other agents that target risk factor for CVD such as LDL cholesterol, blood pressure, diabetes.

Lifestyle programmes have a beneficial effect on cardiovascular risk management and on recurrent cardiovascular events. An improvement of physical activity levels, dietary habits, and smoking cessation showed promising results. In the present era of increasing number of overweight and physically inactive patients, this study confirms the importance of risk factor control through lifestyle modification as a supplement to more intensified drug treatment.

Additional research can take into account adherence to management strategies as well as investigate the effects of multiple interventions. Moreover the lifestyle management strategy require little to no equipment, no expensive medication and can be performed at home or at the convenience of patients.

Further research can examine whether these low-cost strategies are cost-effectiveness compared to other CVD management strategies and demonstrate whether tailored therapies do improve health outcomes and patients adherence.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Maranhão RC, Carvalho PO, Strunz CC, et al. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol 2014;103:76-84. [PubMed]
  2. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1732-41. [Crossref] [PubMed]
  3. Galvano F, Malaguarnera M, Vacante M, et al. The physiopathology of lipoprotein (a). Front Biosci (Schol Ed) 2010;2:866-75. [PubMed]
  4. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655-8. [Crossref] [PubMed]
  5. Scanu AM. Lipoprotein(a): a genetically determined cardiovascular pathogen in search of a function. J Lab Clin Med 1990;116:142-6. [PubMed]
  6. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15. [Crossref] [PubMed]
  7. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904-10. [Crossref] [PubMed]
  8. Røsby O, Aleström P, Berg K. Sequence conservation in kringle IV-type 2 repeats of the LPA gene. Atherosclerosis 2000;148:353-64. [Crossref] [PubMed]
  9. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7. [Crossref] [PubMed]
  10. Lackner C, Boerwinkle E, Leffert CC, et al. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991;87:2153-61. [Crossref] [PubMed]
  11. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013;273:6-30. [Crossref] [PubMed]
  12. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9. [Crossref] [PubMed]
  13. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28. [Crossref] [PubMed]
  14. Russo C, Vacante M, Malaguarnera G, et al. Lipoprotein(a) in cerebral stroke: A review. Acta Medica Mediterranea 2012;28:201-5.
  15. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5. [Crossref] [PubMed]
  16. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57. [Crossref] [PubMed]
  17. Malaguarnera M, Vacante M, Russo C, et al. Lipoprotein(a) in cardiovascular diseases. Biomed Res Int 2013;2013:650989. [Crossref] [PubMed]
  18. Uccello M, Malaguarnera G, Pelligra EM, et al. Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian J Med Paediatr Oncol 2011;32:71-5. [Crossref] [PubMed]
  19. Nordestgaard BG, Chapman MJ, Ray K, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53. [Crossref] [PubMed]
  20. Morishita R, Ishii J, Kusumi Y, et al. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. J Atheroscler Thromb 2009;16:410-8. [Crossref] [PubMed]
  21. Malaguarnera G, Catania VE, Francaviglia A, et al. Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis. Aging Clin Exp Res 2017;29:185-90. [Crossref] [PubMed]
  22. Malaguarnera G, Gagliano C, Bucolo C, et al. Lipoprotein(a) serum levels in diabetic patients with retinopathy. Biomed Res Int 2013;2013:943505. [Crossref] [PubMed]
  23. Nielsen LB, Juul K, Nordestgaard BG. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol 1998;18:641-9. [Crossref] [PubMed]
  24. Tsironis LD, Katsouras CS, Lourida ES, et al. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis 2004;177:193-201. [Crossref] [PubMed]
  25. Wehinger A, Kastrati A, Elezi S, et al. Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 1999;33:1005-12. [Crossref] [PubMed]
  26. Bohl S, Kassner U, Eckardt R, et al. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial 2009;13:129-37. [Crossref] [PubMed]
  27. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470-8. [Crossref] [PubMed]
  28. Serban MC, Sahebkar A, Mikhailidis DP, et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep 2016;6:19188. [Crossref] [PubMed]
  29. Florentin M, Elisaf MS, Rizos CV, et al. L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study. Lipids 2017;52:1-9. [Crossref] [PubMed]
  30. Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013;28:193-9. [Crossref] [PubMed]
  31. Malaguarnera M, Vacante M, Motta M, et al. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism 2009;58:1618-23. [Crossref] [PubMed]
  32. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008;52:24-32. [Crossref] [PubMed]
  33. Fraley AE, Schwartz GG, Olsson AG, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol 2009;53:2186-96. [Crossref] [PubMed]
  34. Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother 2009;10:1875-82. [Crossref] [PubMed]
  35. Yeang C, Clopton PC, Tsimikas S. Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk. J Clin Lipidol 2016;10:1389-96. [Crossref] [PubMed]
  36. Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013;14:93-9. [Crossref] [PubMed]
  37. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol 2010;21:487-91. [Crossref] [PubMed]
  38. Keller C. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Ther Apher Dial 2007;11:2-8. [Crossref] [PubMed]
  39. Anedda FM, Velati A, Lello S, et al. Observational study on the efficacy of tibolone in counteracting early carotid atherosclerotic lesions in postmenopausal women. Horm Res 2004;61:47-52. [PubMed]
  40. Demirol A, Guven S, Guvendag Guven ES, et al. Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study. Fertil Steril 2007;87:842-8. [Crossref] [PubMed]
  41. Berthold HK, Laudes M, Krone W, et al. Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One 2011;6:e24719. [Crossref] [PubMed]
  42. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-16. [Crossref] [PubMed]
  43. Alonso R, Andres E, Mata N, et al. SAFEHEART Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014;63:1982-9. [Crossref] [PubMed]
  44. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17. [Crossref] [PubMed]
  45. Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15. [Crossref] [PubMed]
  46. Berthold HK, Gouni-Berthold I. Lipid-lowering drug therapy in elderly patients. Curr Pharm Des 2011;17:877-93. [Crossref] [PubMed]
  47. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006. [Crossref] [PubMed]
  48. Perrot N, Verbeek R, Sandhu M, et al. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis 2017;256:47-52. [Crossref] [PubMed]
Cite this article as: Malaguarnera G, Latteri S, Catania VE, Malaguarnera M. Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels. J Thorac Dis 2017;9(8):2332-2336. doi: 10.21037/jtd.2017.08.67